Jan 30, 2026 3-5pm ET
Friday on The Robert Scott Bell Show:
Special Guest: Zach Bynum
ACES Team – from Disney (Kylo Ren) and the Ritz Carlton to Better Way Health. The Prince of Customer Service.
Zach Bynum is a member of the ACES (Amazing Customer Experience Specialists) Team at Better Way Health, a company renowned for its premium, evidence-based supplements, particularly their flagship product, BWH-85™ Beta Glucan. In his role, Zach is dedicated to providing exceptional customer service, ensuring that clients receive personalized support and guidance on their wellness journeys. His commitment to excellence and transparency aligns with Better Way Health’s core values, contributing to the company’s mission of enhancing lives through superior health products and customer experiences.
Special Guest: Reggie Black
From IT to BWH – leveraging the power of relationships to grow an ecommerce business.
Reggie Black is a Co-Owner of Better Way Health and the Cancer Data Foundation. A seasoned Entrepreneur, his career spans Over 20 Years in various sectors of Wellness and Technology. Having served thousands of people worldwide, Reggie has attained a unique level of business expertise that specializes in a first-class customer experience. Reggie is committed to teaching and inspiring others in their pursuit of abundant life; he consistently shares his insight across a variety of platforms, from natural health summits to executive seminars.
Special Guest: Adrian Waldron
From Best Buy to AI – He is using technology and AI to help optimize the business and help get the word out about Beta Glucan to the world.
In 2023, I decided to completely remove social media & infinite scrolling from my life. Since then, I’ve used this website as a means to share my life experiences.
I’m a follower of Jesus, Husband, Father—and obsessed with business. By God’s grace I’ve had opportunities to learn from entrepreneurs that win at home and in business.
I’m blessed to serve various businesses as a strategic technology partner focused on using tech to solve problems + drive scale. In everything I do–whether it’s leading a business or leading my family of five–my goal is excellence.
I often think about Joseph in Potifar’s house; everything he put his hands to do was blessed. I pray for a similar blessing with everything I put my hands to do.
If you like business, technology, productivity, faith, fatherhood – or anything about living an intentional life – you’re right at home!
Special Guest: Taylor Morris
CXO – Customer Experience Officer – from Packing and Shipping to leading the ACES Team – Taylor oversees every inch of the customer journey.
As COO of Better Way Health, Taylor creates and Implements business operations and policies that reinforce our company culture. He ensures we stick to our core values and provides resources to elevate our team members in their respective roles. He is the day-to-day backbone of our world-class customer service and a seasoned authority on Beta Glucan.
Special Guest: Jordan Merrick
From running a 70-acre outdoor facility at FSU to now sitting behind a laptop building out beta glucan education, our newest team member and the story of how he ended up here through a family connection.
Hour 1
Arizona Introduces Bill Classifying mRNA Injections as Biological Weapons, Felonies, and Acts of Terrorism The article reports that a bill introduced in the Arizona House of Representatives, House Bill 2974, would classify modified messenger RNA injections and products as biological agents, weapons of mass destruction, and acts of terrorism under state law, making their manufacture, possession, or distribution a Class 2 felony. Titled the “Sansone mRNA Bioweapons Prohibition Act,” the legislation amends Arizona’s criminal code to explicitly include modified mRNA products, including COVID-19 shots and self-amplifying or self-replicating mRNA technologies, within statutes governing biological weapons, toxins, vectors, terrorism, and racketeering. The bill provides no exemptions for FDA approval, emergency authorizations, medical use, research, or public health programs, and authorizes prosecution under Arizona’s terrorism statutes, including the possibility of life imprisonment if a violation results in death. It also mandates enforcement by state and local officials, removing prosecutorial discretion and imposing criminal liability for nonfeasance on officials who knowingly fail to investigate or enforce violations after receiving evidence. The legislation grants Arizona residents standing to seek injunctive relief, declaratory relief, and monetary damages against the state or officials for lack of enforcement. The article notes that the bill was introduced by Representative Rachel Jones Keshel and authored by Dr. Joseph Sansone, who has seen similar legislation introduced in other states as part of what is described as a multistate effort. It further outlines the bill’s broad definition of modified mRNA, encompassing current COVID-19 injections, gene-altering technologies, and future gene therapy products for infectious diseases, and emphasizes that the legislature explicitly declares its intent to prohibit such products as a matter of public peace, health, and safety through an emergency designation.
Iowa Bill Would Require Medical Examiners to Include Vaccine Records in Infant Death Investigations An Iowa legislative proposal would mandate that medical examiners include a deceased infant’s vaccination history as part of routine death investigations, with proponents arguing that this requirement would ensure that immunization status is considered alongside other potential factors when determining cause of death for babies, and that full transparency is necessary for public confidence and accurate mortality data. The bill, introduced in the state legislature, seeks to require coroners and medical examiners to compile and report vaccine records to the Iowa Department of Public Health and into official death reports so that any temporal relationship between vaccination and death could be documented and reviewed. Supporters quoted in the article claim that current practice often omits vaccine history from death investigations, leaving families and researchers without a complete picture of circumstances surrounding unexplained infant fatalities, and they frame the legislation as a measure to improve data quality, promote accountability, and remove perceived barriers to investigating possible vaccine-related factors. Opponents of the bill, including some physicians and public health advocates, argue that adding mandated vaccine record reporting could complicate death investigations without clear evidence that vaccination is causally linked to unexplained infant deaths, and they warn that emphasizing vaccination status in official reports may inadvertently mislead families or the public and fuel unfounded concerns about vaccine safety. The debate reflects broader national tensions over how vaccine data should be collected, analyzed, and communicated in sensitive cases, particularly when vaccine hesitancy and public trust in immunization programs are highly contested issues.
Pharmaceutical Companies Are Spending Big Money on Weight-Loss Drug Lobbying Pharmaceutical companies that produce popular GLP-1 weight-loss and metabolic drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound have dramatically increased their lobbying efforts with the U.S. federal government as scrutiny around pricing and coverage intensifies, with lobbying disclosures showing that manufacturers like Novo Nordisk and Eli Lilly spent millions of dollars in late 2025 advocating on issues related to drug pricing and Medicare coverage for GLP-1 therapeutic products even as they publicly reached pricing deals with the Trump administration; Novo Nordisk reported spending about $2.12 million on federal lobbying in the fourth quarter of 2025 and Eli Lilly about $2.2 million, with firms also pressing on legislative matters such as the Treat and Reduce Obesity Act that would expand Medicare Part D coverage for obesity medications. Companies without marketed GLP-1 products, including Boehringer Ingelheim and Johnson & Johnson, also lobbied on weight-loss drug pricing and related issues, indicating broader industry interest in how GLP-1s are regulated, reimbursed and integrated into health care policy. The lobbying activity occurred in a context where the Trump administration has made lowering prescription drug prices a priority, including issuing executive orders for most-favored-nation pricing and announcing agreements with manufacturers to reduce the cost of GLP-1 drugs under programs such as TrumpRx, and where lawmakers like U.S. Rep. Mike Kelly supported legislation to expand Medicare coverage of weight-loss medications. The article suggests that behind-the-scenes advocacy reflects industry concerns that government pressure on prices could affect profit margins and shape future access to these high-demand medications, with manufacturers balancing public cooperation on price reductions with continued efforts to influence policy and coverage decisions in Congress and federal agencies.
Public health must bridge the divide with groups who mistrust science A commentary in The BMJ emphasizes that public health authorities need to do a better job of engaging with and understanding communities that mistrust scientific institutions and health messaging, arguing that dismissing or alienating these groups undermines efforts to control disease and promote wellbeing. The author notes that mistrust of science and medicine is shaped by historical grievances, cultural identity, personal experiences with the health system, and perceived lack of respect for individual agency and community values, and that these factors can lead people to reject or question public health interventions even when the underlying evidence is strong. Rather than framing distrust as ignorance or blameworthy behavior, the piece suggests that health professionals should adopt empathy, dialogue, and partnership as core strategies, recognizing that communication failures — including oversimplified messaging, condescension, or dismissive responses to concerns — often exacerbate skepticism and disconnection. The article calls for deliberate, sustained bridge-building efforts that meet communities where they are, incorporate local leaders and trusted voices into outreach, and validate individuals’ experiences while transparently acknowledging uncertainties and limitations in current scientific understanding. It also challenges the default assumption that expert consensus automatically translates into public acceptance, urging a shift toward inclusive, two-way conversations that respect values and address fear, identity, and historical context. The commentary concludes that strengthening trust between public health institutions and skeptical populations is not only an ethical priority but practical medicine, essential for improving uptake of health interventions and reducing the social polarization of science and health policy debates.
Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!
On The Robert Scott Bell Show today, we highlight Vinca minor — a remedy Boericke describes as acting primarily on the skin of the scalp, especially in children.
Its keynote picture centers on thick crusts, offensive, sticky oozing, and sensitive scalp eruptions, most characteristically seen in crusta lactea and related eczematous conditions.
Download the Information Sheet
Hour 2
Why Soda Is Cheaper Than Water, What That Says About America’s Food System The article explains that in many parts of the United States sugary sodas and other sweetened beverages are often cheaper than bottled water or healthier drink options, a pricing disparity the authors say reflects deep dysfunction in the American food and beverage system that prioritizes processed, high-profit products over basic nutrition and public health. It notes that the low retail prices of sodas are enabled by decades of federal agricultural subsidies that reduce the cost of key ingredients such as corn syrup and sugar, while water, milk and other healthy beverages do not benefit from comparable subsidy programs, creating an economic incentive structure that steers consumers — particularly lower-income families — toward cheaper, calorie-dense, nutrient-poor options. The article also highlights the role of Big Soda’s marketing muscle, which leverages large advertising budgets, brand loyalty, and pervasive shelf placement to normalize consumption of sugary drinks, and contends that such companies exercise disproportionate influence on food policy and dietary guidelines relative to producers of healthier alternatives. Experts quoted in the piece argue that the result is not just a matter of consumer preference but a structural issue where public resources underwrite products that contribute to obesity, diabetes, heart disease and other chronic conditions, while healthier foods and beverages face market disadvantages and higher upfront costs, reducing access and affordability. It connects these pricing inequities to broader critiques of U.S. food policy that emphasize the need for reforms — such as shifting subsidies toward fruits, vegetables and clean water infrastructure, regulating sugar content, and supporting community-based food systems — to realign economic incentives with public health goals and address health disparities linked to diet and socioeconomic status.
The Hidden Chemical Partnership: How Glyphosate and Fluoride Collide Inside the Human Body The article asserts that glyphosate and fluoride interact in the human body in ways that amplify their individual toxic effects, arguing that these two ubiquitous chemicals—one widely used as an herbicide on crops and the other commonly added to drinking water and found in dental products—can synergistically disrupt endocrine function, impair detoxification pathways, and contribute to chronic disease when present together at levels typical of modern environmental exposures. It explains that glyphosate, the active ingredient in many herbicides, can chelate minerals and interfere with cytochrome P450 enzymes involved in hormone synthesis and detoxification, while fluoride can accumulate in bone and soft tissues and has been linked in some studies to thyroid dysfunction, neurodevelopmental effects and reduced IQ in children. The piece suggests that their combined presence may exacerbate biological stress by increasing oxidative damage, compounding endocrine disruption, and impairing the body’s ability to clear toxicants, presenting this interaction as a hidden chemical partnership seldom acknowledged in regulatory risk assessments that typically evaluate single chemicals in isolation rather than complex mixtures. It critiques current safety standards, claiming they underestimate real-world exposures and fail to account for interactive effects, and calls for updated toxicological evaluation methods that consider combined chemical burdens. The article also advocates for policy changes to reduce exposure to both glyphosate and fluoride and to prioritize independent research into their long-term health impacts, framing this issue as part of a broader push against regulatory frameworks it views as too lax and influenced by industrial interests.
Syngenta Settles Bellwether US Trial Over Paraquat Links to Parkinson’s On the eve of what would have been the first bellwether trial in Philadelphia testing claims that the herbicide paraquat causes Parkinson’s disease, agrochemical manufacturer Syngenta reached a settlement with the plaintiff who alleged long-term exposure to the weed killer led to his incurable neurological condition, resolving the case before jurors could hear evidence in court. The lawsuit, brought by a retired landscaper, was expected to be a highly watched examination of scientific research and internal corporate documents linking paraquat products — including Syngenta’s Gramoxone brand — to increased Parkinson’s risk, and such a trial was seen as a pivotal moment in thousands of related cases pending nationwide that assert manufacturers failed to warn users of potential neurological harms. Reports indicate that while the settlement terms have not been publicly disclosed, Syngenta’s decision to settle ahead of trial reflects a strategic move to avoid a jury verdict that could influence the broader litigation and potentially shape negotiations over the many other paraquat claims still active in both state and federal courts. The litigation has unfolded against a backdrop of ongoing regulatory review and growing legislative efforts in several states, including Pennsylvania, Missouri and Vermont, to ban or restrict paraquat amid health and safety concerns, highlighting the intersection of product liability, public health debate, and environmental policy as advocates press for stronger controls on a pesticide still widely used in U.S. agriculture despite bans in other countries and longstanding toxicity concerns.
Innovative Poop Pills Show Promising Results in Clinical Trials for Cancer Patients Early clinical trial results suggest that oral capsules containing beneficial bacteria derived from healthy stool samples — often called “poop pills” — may help improve outcomes for some cancer patients, particularly by enhancing responses to immunotherapy and potentially reducing side effects, as researchers have reported encouraging signals in initial human studies exploring the impact of microbiome modulation on treatment efficacy. The trials involve administering standardized capsules of selected gut microbes to individuals undergoing cancer treatments such as immune checkpoint inhibitors, based on evidence that the composition of the gut microbiome can influence how a patient’s immune system responds to these therapies and affects inflammation and overall health. Study investigators observed that patients who received the microbiome capsules showed higher rates of favorable immune responses compared with controls, and some participants experienced reductions in treatment-related toxicity, although researchers caution that sample sizes remain small and longer follow-up is needed to determine durability of benefits, optimal dosing strategies, and which specific microbial communities or metabolites are most therapeutic. The article notes that the science of microbiome research is rapidly evolving and holds promise for a range of applications beyond cancer, but emphasizes that poop pill development faces challenges including ensuring safety, regulatory pathways, and consistent manufacturing of live biologic products, and that additional randomized trials are underway to confirm findings and address unanswered questions before these interventions become broadly recommended in clinical practice.
Remember Friends, The Power to Heal is Yours!
